Citations

Clear

171 citation(s) found for "Moss, M".

Impact of Successful Recanalization and Clinical Outcomes of Patients With Acute Ischemic Stroke with 5 or More Thrombectomy Passes
Uchida, Kazutaka , Kasab, Sami Al , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Grossberg, Jonathan A , Tanweer, Omar , Polifka, Adam , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Williamson, Richard , Navía, Pedro , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Collaborators, for the Stroke Thrombectomy and Aneurysm Registry (STAR), Navia, Pedro , Sowlat, Mohammad‐Mahdi , Matsukawa, Hidetoshi , Elawady, Sameh Samir , Alawieh, Ali , Cunningham, Conor M. , Jabbour, Pascal , Wolfe, Stacey Q , Shaban, Amir , Arthur, Adam Stephen , Cuellar, Hugo , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael R. , Leacy, Reade De , Yoshimura, Shinichi , Collaborators, for the Stroke Thrombectomy and Aneurysm Registry (STAR)

Mayo Clinic

Stroke: Vascular and Interventional Neurology | November 21, 2023 | Volume: 4 | Issue: 1 | Pages: No page available

10.1161/svin.123.001107 | PMID 41586058 Get It

Background As the number of thrombectomy passes increases during endovascular therapy (EVT) for acute stroke, neurointerventionalists must weigh the risks of potential complications against the risk of failing to recanalize the affected vessel. Thus, we investigated the effectiveness and safety of EVT for patients with acute stroke in which ≥5 EVT passes were performed. Methods This retrospective cohort study from January 2013 to December 2022 included 31 thrombectomy‐capable centers. Patients in whom ≥5 EVT passes were made were included in the analysis. The patients with successful recanalization defined as modified Thrombolysis in Cerebral Infarction ≥2b at 5, 6, 7, or more passes were compared with unsuccessful recanalization. We also compared procedure time, separated by 30 minutes. Primary outcome was a favorable 90‐day outcome (modified Rankin scale score of 0–2). Secondary outcomes were intracranial hemorrhage and death. Results A total of 407 patients met the inclusion criteria, of which 175 were women (43.1%); the mean age was 67.3 years. In 265 (65.1%) patients, successful recanalization was achieved: 134 patients with 5 passes, 67 patients with 6 passes, and 64 with ≥7 passes. Intravenous recombinant tissue plasminogen activator administration was more common in the unsuccessful recanalization group (successful recanalization with 5, 6, and ≥7 EVT passes and unsuccessful recanalization: 35.3%, 30.3%, 18.8%, and 45.4%, respectively). Successful recanalization with 5, 6, and ≥7 EVT passes was associated with favorable outcome compared with unsuccessful recanalization group (adjusted odds ratio successful recanalization with 5, 6, and ≥7 EVT passes to unsuccessful recanalization [95% CIs]: 8.29 [2.13–32.3]; 14.0 [3.27–60.3]; and 5.26 [1.12–24.8], respectively). However, symptomatic intracranial hemorrhage was not significantly different between the groups. Regarding procedure time, favorable outcome was not significantly different in each group, while symptomatic intracranial hemorrhage occurred more frequently in the 60 to 89 minutes group compared with the <30 minutes group (adjusted odds ratio, 60–89 minutes group to <30 minutes group [95% CI]: 5.86 [1.09–31.6]). Conclusion These findings suggest that a benefit in outcome persists for recanalization, without significant increase in complications. In addition, there was no significant difference in favorable outcomes among procedure time.
Review of Portopulmonary Hypertension Prevalence at Mayo Clinic in Arizona, Florida, and Minnesota
Saunders, Hollie , Cartin‐Ceba, Rodrigo , Moss, James , Krowka, Michael J. , Helgeson, Scott A. , DuBrock, Hilary M. , Cajigas, Héctor , Burger, Charles D.

Mayo Clinic

C63. THINKING OUTSIDE THE BOX: NEW INSIGHTS INTO SUBGROUPS OF PULMONARY HYPERTENSION | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A5532-A5532

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5532 Get It

Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
Morcos, Peter N. , Schlender, Jan, Burghaus, Rolf , Moss, Jonathan, Lloyd, Adam , Childs, Barrett H. , Macy, Margaret E. , Chung, John, Garmann, Dirk , Schlender, Jan‐Frederik , Moss, Jonathan, Reid, Joel M.

Mayo Clinic

Clinical and Translational Science | April 12, 2023 | Volume: 16 | Issue: 7 | Pages: 1197-1209

10.1111/cts.13523 | PMID 37042099 Get It

AbstractCopanlisib is an intravenously administered phosphatidylinositol 3‐kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model‐informed approach was undertaken to support and confirm an empirically selected starting dose of 28 mg/m2 for pediatric patients ≥1 year old, corresponding to 80% of the adult recommended dose adjusted for body surface area. An adult physiologically based pharmacokinetic (PBPK) model was initially established using copanlisib physicochemical and disposition properties and clinical pharmacokinetics (PK) data and was shown to adequately capture clinical PK across a range of copanlisib doses in adult cancer patients. The adult PBPK model was then extended to the pediatric population through incorporation of age‐dependent anatomical and physiological changes and used to simulate copanlisib exposures in pediatric cancer patient age groups. The pediatric PBPK model predicted that the copanlisib 28 mg/m2 dose would achieve similar copanlisib exposures across pediatric ages when compared with historical adult exposures following the approved copanlisib 60 mg dose administered on Days 1, 8, and 15 of a 28‐day cycle. Clinical PK were collected from a phase I study in pediatric patients with relapsed/refractory solid tumors (aged ≥4 years). An established adult population PK model was extended to incorporate an allometrically‐scaled effect of body surface area and confirmed that the copanlisib maximum tolerated dose of 28 mg/m2 was appropriate to achieve uniform copanlisib exposures across the investigated pediatric age range and consistent exposures to historical data in adult cancer patients. The model‐informed approach successfully supported and confirmed the copanlisib pediatric dose recommendation.
Evaluating In-home Assistive Technology for Dementia Caregivers
Levenson, Robert W. , Chen, Kuan‐Hua , Levan, Darius Tran, Chen, Enna Y., Newton, Scott L. , Paul, Deepak, Yee, Claire , Brown, Casey L. , Merrilees, Jennifer , Wang, Gene, Yee, Claire I., Yee, Claire , Levenson, Robert W , Paul, Deepak, Moss, David

Mayo Clinic

Clinical Gerontologist | February 3, 2023 | Volume: 47 | Issue: 1 | Pages: 78-89

10.1080/07317115.2023.2169652 | PMID 36732317 Get It

Outcomes of endoscopic retrograde cholangiography and percutaneous transhepatic biliary drainage in liver transplant recipients with a Roux-en-Y biliary-enteric anastomosis
Kohli, Divyanshoo R., Aqel, Bashar , Segaran, Nicole , Harrison, M. Edwyn , Fukami, Norio , Faigel, Douglas O. , Moss, Adyr A. , Mathur, Amit K. , Hewitt, Winston R. , Katariya, Nitin , Pannala, Rahul , Kohli, Divyanshoo Rai , Aqel, Bashar A. , Segaran, Nicole L , Moss, Adyr , Mathur, Amit , Hewitt, Winston , Harrison, M Edwyn , Faigel, Douglas O , Fukami, Norio , Katariya, Nitin N

Mayo Clinic

Annals of Hepato-Biliary-Pancreatic Surgery | October 17, 2022 | Volume: 27 | Issue: 1 | Pages: 49-55

10.14701/ahbps.22-037 | PMID 36245257 Get It

Early Versus Usual Palliative Care Consultation in the Intensive Care Unit
Helgeson, Scott A. , Burnside, Rebecca, Robinson, Maisha T. , Mack, Rachel C., Ball, Colleen T. , Moss, John E. , Helgeson, Scott A , Guru, Pramod

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | July 14, 2022 | Volume: 40 | Issue: 5 | Pages: 544-551

10.1177/10499091221115732 | PMID 35833450 Get It

Objectives Palliative Medicine involvement in MICU patients have improved length of stay and mortality, but with varying effects on specific patient decision outcomes, such as, advance care planning. These studies have utilized Palliative Medicine later in the hospital or ICU course, with some evidence showing that earlier involvement resulted in better results. The purpose of this study was to evaluate the benefits of early (within 24 hours) palliative care consultation in medical ICU (MICU) patients to clinical and satisfaction outcomes. Methods An unblinded randomized study performed in the MICU in one academic hospital in the USA. Ninety-one adult patients admitted to MICU received a Palliative care medicine consultation within 24 hours as the intervention. Measurements and results Ninety-one patients admitted to the MICU underwent randomization with 50 patients randomly assigned to receive Palliative Medicine consultation and 41 patients randomly assigned to receive standard-of-care based on predefined criteria. The median satisfaction score was 23 points higher for the patients in the intervention group (P < .001). The median length of MICU stay was 5 days shorter in the intervention group compared to the control group (95% CI; 1 day to 18 days, P = .018). Advance care planning was completed in the hospital for 34% of patients in the intervention arm and 12% of patients in the controls arm (absolute risk difference 22%, 95% CI 4% to 37%, P = .016). Conclusion Early Palliative Medicine consultation within 24 hours of MICU admission showed significant benefits to patients by improving satisfaction and decreasing length of stay. This study provides evidence that Palliative Medicine involvement earlier in the course of severe disease is important. Further studies in other types of intensive care units (neurological and Cardiovascular) are necessary to determine their impact.
Remote 6-minute-Walk Testing in Patients with Pulmonary Hypertension: Further Validation Needed?
Helgeson, Scott A. , Moss, John E. , Zeiger, Tonya K., Taylor, Bryan J , Helgeson, Scott A , Burger, Charles D. , Taylor, Bryan J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 24, 2022 | Volume: 206 | Issue: 5 | Pages: 650-651

10.1164/rccm.202204-0762le | PMID 35608525 Get It

Dexmedetomidine as a Potential Cause of Central Sleep Apnea
Balavenkataraman, A., Gopal, Neethu , Moss, James , Arunthari, Vichaya, Colaco, Brendon

Mayo Clinic

C63. SLEEP GEMS: CASE REPORTS FROM THE WORLD OF SLEEP MEDICINE | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4596-A4596

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4596 Get It

Association Between Submaximal Exercise Gas Exchange and Clinical Worsening Events in Patients with Pulmonary Arterial Hypertension
Call, Justin T. , Saunders, Hollie , Zeiger, Tanya, Moss, James , Burger, C.D., Taylor, Bryan J. , Helgeson, Scott A.

Mayo Clinic

B106. UNION SQUARE: OBSERVATIONAL STUDIES AND CLINICAL TRIALS IN PULMONARY HYPERTENSION | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3602-A3602

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3602 Get It

Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation
Katariya, Nitin , Chascsa, David M. , Giorgakis, Emmanouil , Aqel, Bashar , Moss, Adyr A. , Usón, Pedro Luiz Serrano , Mathur, Amit K. , Lizaola-Mayo, Blanca C, Giorgakis, Emmanouil , Mathur, Amit , Uson, Pedro L S , Katariya, Nitin N , Lizaola‐Mayo, Blanca , Aqel, Bashar A. , Borad, Mitesh J.

Mayo Clinic

Cancers | April 19, 2022 | Volume: 14 | Issue: 9 | Pages: 2056

10.3390/cancers14092056 | PMID 35565184 Get It

Hepatocellular Carcinoma (HCC) is the most common liver malignancy and third leading cause of cancer death worldwide. For early- and intermediate-stage disease, liver-directed therapies for locoregional control, or down-staging prior to definitive surgical therapy with hepatic resection or liver transplantation, have been studied broadly, and are the mainstays of current treatment guidelines. As HCC incidence has continued to grow, and with more patients presenting with advanced disease, our current treatment modalities do not suffice, and better therapies are needed to improve disease-specific and overall survival. Until recently, sorafenib was the only systemic therapy utilized, and was associated with dismal results. The advent of immuno-oncology has been of significant interest, and has changed the paradigm of therapy for HCC. Lately, combination regimens including atezolizumab plus bevacizumab; durvalumab plus tremelimumab; and pembrolizumab plus Lenvatinib have shown impressive responses of between 25–35%; this is much higher than responses observed with single agents. Complete responses with checkpoint inhibitor therapy have been observed in advanced-stage HCC patients. These dramatic results have naturally led to several questions. Can or should checkpoint inhibitors, or other immunotherapy combinations, be used routinely before resection or transplant? Is there a synergistic effect of immunotherapy with locoregional therapy, and will pre-treatment increase disease-free survival after surgical intervention? Is it immunologically safe to use these therapies prior to transplantation? Much is still to be learned in terms of the dosing, timing, and overall utility of the use of immune checkpoint inhibitors for pre-transplant care and down-staging. More studies will be needed to understand the management of adverse events while maximizing the therapeutic window of these agents. In this review, we look at the current data on therapy with immune checkpoint inhibitors in advanced HCC, with a focus on pre-transplant treatment prior to liver transplant.